Elucidation of molecular targets based on epithelial-mesenchymal transition for the treatment of renal cell carcinoma

2014 Fiscal Year Final Research Report

• Project/Area Number: 24390374
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Keio University
• Principal Investigator: OYA Mototsugu 慶應義塾大学, 医学部, 教授 (00213885)
• Co-Investigator(Kenkyū-buntansha): MIKAMI Shuji 慶應義塾大学, 医学部, 講師 (20338180) ; KIKUCHI Eiji 慶應義塾大学, 医学部, 講師 (10286552) ; NAKAGAWA Ken 東京歯科大学, 歯学部, 教授 (50227740) ; MIZUNO Ryuichi 慶應義塾大学, 医学部, 講師 (60383824) ; ASANUMA Hiroshi 慶應義塾大学, 医学部, 講師 (70245570) ; MIYAJIMA Akira 慶應義塾大学, 医学部, 准教授 (90245572) ; NAGATA Hirohiko 慶應義塾大学, 医学部, 研究員 (90265900)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 腎細胞癌 / 分子標的治療 / 薬剤耐性 / CD44 / mTOR

Outline of Final Research Achievements

Molecular targeted agents are widely used and better survival benefits are shown for the treatment of metastatic renal cell carcinoma (RCC). However, there are still hurdles to conquer RCC because survival cancer cells survive. The phenotype survival cancer cells look like sarcoma suggesting epithelial- mesenchymal transition. We found out that CD44 is up-regulated in the cells where Tumor Necrosis Factor (TNF)-α　induces the expression.

Free Research Field

泌尿器科学、腫瘍学、腎臓病学、透析医学